Abstract: A throat drop comprises from 60 to 95% of a candy shell and from 5 to 40% of an aqueous filling, by weight of the drop. The filling comprises, by weight, by 8 to 20% water, from 50 to 85% bulk sweetener, and sufficient emulsifier to provide a contact angle of from 90° to 120°, the filling having a contact angle of greater than 120° in the absence of the emulsifier. The reduction in contact angle relative to a composition without the emulsifier provides an improved perception of liquidity of the filling.

Abstract: The present invention relates to frozen hydrated par-fried potato strips comprising about 35% to about 55% moisture which when oven finished have substantially the same internal and surface texture as deep fried French fries. More particularly this invention relates to par-fried potato strips for subsequent finishing in an oven prior to consumption prepared by: (a) parfrying potato strips at an oil temperature of from about 270.degree. F. (132.degree. C.) to about 385.degree. F. (196.degree. C.) for a time sufficient to reduce the moisture content of the par-fries to from about 30% to about 50%, (b) hydrating the surface of said par-fries until the weight thereof is increased by from about 1% to about 12%, and (c) freezing said hydrated par-fries. The frozen, hydrated par-fries comprise from about 35% to about 55% moisture.

Abstract: The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical composition which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower gastrointestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which occasionally accompanies the oral administration of risedronate active ingredients.

Abstract: The present invention provides methods of increasing bone mass in a human or other animal subject afflicted with osteoporosis, comprising a thirty(30)-day treatment period, comprised of a parathyroid hormone administration regimen and a bisphosphonate administration regimen, wherein(a) said parathyroid hormone administration regimen comprises the administration to said subject of parathyroid hormone at one or more level of from about 4 IU/kg per day to about 15 IU/kg per day that said parathyroid hormone is administered, provided that said parathyroid hormone is administered at least one day every seven days of every said thirty(30)-day treatment periods; and wherein(b) said bisphosphonate administration regimen comprises the administration to said subject of a bisphosphonate at a level of from about 0.0005 mgP/kg to about 1.0 mgP/kg per day that said bisphosphonate is administered, provided that said bisphosphonate is administered at least 1 day of every said thirty(30)-day treatment period.